South Korea Remains MSCI Emerging Market Despite Reform Progress 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Wall Street Ends Mixed as Tech Stocks Struggle Ahead of Micron Earnings 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Oil Prices Drop as Middle East Supply Recovery Eases Market Concerns 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
South Korea’s KOSPI Rebounds as Samsung and SK Hynix Lead Tech Stock Recovery 
Yen Near 40-Year Low as USD/JPY Approaches Key 162 Level, Raising Intervention Concerns 
U.S.-Iran Diplomacy Helps Drive Gasoline Prices Down 15% From May Highs 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Australia Inflation Cools in May, But Core CPI Keeps RBA Rate Hike Risks Alive 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Gold Drops Below $4,000 as Strong US Dollar and Fed Rate Hike Expectations Pressure Bullion 
White House Seeks $87.6 Billion Emergency Funding for Iran War, Farmers, and Ebola Response 
Samsung Biologics and Samsung C&T Corp. are investing in Senda Biosciences, a US-based biotechnology company. The two Samsung subsidiaries are set to spend $15 million on the project.
As per The Korea Times, Samsung Biologics and Samsung C&T have set up an investment fund for Senda Biosciences as part of their efforts to strengthen the core technology needed to develop and produce next-generation biopharmaceutical products.
The investment was announced on Wednesday, Aug. 17. The South Korean biotech firm said that it has jointly created the Life Science Fund with the construction and engineering company. They have made the decision to invest in the said American biotech firm after noting it has secured a first-rate programmable drug delivery platform.
Aside from Samsung Life Science Fund, Qatar Investment Authority, Stage 1Ventures, and Bluwave Capital have also invested in the company's Series C financing. Others that have participated in the financing are existing investors such as the State of Michigan Retirement System, Mayo Clinic, Alexandria Venture Investments, Partners Investment, and Longevity Vision Fund. Senda Biosciences raised a total of $266 million in funds as of the moment.
"Senda is pioneering the development of comprehensively programmable medicines with the potential to reach previously inaccessible cells, tissues, and organs," Senda Biosciences' chief executive officer and partner at Flagship Pioneering, Guillaume Pfefer, Ph.D., said in a press release.
He added, "We believe our approach could transform the lives of patients in need of novel treatments, and so we're delighted to have attracted support from investors who recognize this potential and its significance."
Senda Biosciences also operates a platform technology that utilizes artificial intelligence (AI) and machine learning technologies to nanoparticle big data in animals, plants, and bacteria to make an advanced drug delivery system. It is also developing new therapeutic drugs and mRNA vaccines.
Finally, Samsung Biologics has plans to build up its partnership with Senda Biologics once the development of new drugs through the latlatter'schnology commences. Senda was established by Flagship Pioneering which is also known as the founder of Moderna vaccine manufacturer.
